Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Colorectal Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

dactolisib 2Everolimus 2surufatinib 1spartalizumab 1pasireotide 1ganitumab 1fosbretabulin 1cixutumumab 1TH 302 1PM 00104 1ONC206 1Fentanyl 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors, Primitive × cixutumumab × Clear all
NCT00668148 2018-07-17

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Eli Lilly and Company

Phase 2 Completed
113 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡